About Cortex
Cortex is a Healthcare company based in Santa Clara (United States) founded in 2023, and was acquired by Boston Scientific in November 2024. Cortex is focused on transforming atrial arrhythmia diagnosis and treatment. It operates on a HealthTech model. Its chief executive, as recorded, is Duke Rohlen. Cortex offers products and services including OptiMap System. Its focus areas include Medical Devices and Cardiovascular Devices. Its competitors include Adagio Medical, Farapulse and Affera; 2 of its 3 listed competitors have raised funding.
Company details
Cortex is engaged in developing innovative solutions for the diagnosis and treatment of atrial arrhythmias. The company specializes in electrographic flow (EGF) mapping technology through its OptiMap System, which is designed to visualize and personalize treatment for atrial fibrillation. By leveraging AI and advanced algorithms, Cortex aims to optimize clinical outcomes in the cardiovascular sector, particularly for complex cases where standard approaches are insufficient. Their solutions are integrated into medical workflows to support physicians in identifying critical triggers and drivers of arrhythmias.
- Headquarters Santa Clara, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website cortexep.com
- Social LinkedIn X
- Acquired by Boston Scientific (Nov 2024)
- Investors
- Acquired byBoston Scientific
(Nov 2024)
Products & Services of Cortex
Cortex offers a comprehensive portfolio of products and services, including OptiMap System.
Electrographic flow mapping system for atrial fibrillation treatment.
Investors in Cortex
Cortex has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Boston Scientific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Wide range of medical devices | 1979 | bostonscientific.com | Marlborough, United States |
Investor details for Cortex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cortex
4 people are tracked at Cortex (2 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Duke Rohlen | CEO | Leadership |
Patricia Chen | R&d Director | Leadership |
Katherine Thompson | Sr. R&d Manager | Team |
Ken Berliner | R&d Manager | Team |
Complete people profiles for Cortex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cortex
2 dated milestones of Cortex across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Cortex is founded.
- Exit Acquired by Boston Scientific.
Competitors of Cortex
Cortex has 3 listed competitors in our database, 2 of them funded. They include Adagio Medical, Farapulse and Affera.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adagiomedical.com | 2011 | Laguna Hills, United States | $72.14M | 72 | Cardiovascular therapies are developed by Adagio Medical in stealth mode. | |
| farapulse.com | 2014 | Menlo Park, United States | $36.3M | Devices for cardiac ablation via pulsed field technology are developed. | ||
| affera.com | 2014 | Boston, United States | 30 | Devices for treating heart rhythm disorders are developed. |
Detailed competitors of Cortex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Cortex (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cortex
Cortex was founded in 2023.
Cortex is headquartered in Santa Clara, United States. It is registered at Santa Clara, California, United States.
Duke Rohlen is the CEO of Cortex, as recorded in our data.
Cortex is engaged in developing innovative solutions for the diagnosis and treatment of atrial arrhythmias. The company specializes in electrographic flow (EGF) mapping technology through its OptiMap System, which is designed to visualize and personalize treatment for atrial fibrillation. By leveraging AI and advanced algorithms, Cortex aims to optimize clinical outcomes in the cardiovascular sector, particularly for complex cases where standard approaches are insufficient. Their solutions are integrated into medical workflows to support physicians in identifying critical triggers and drivers of arrhythmias.
Cortex's top competitors include Adagio Medical, Affera and Farapulse.
Cortex offers OptiMap System.
Cortex has 1 investor. Key investors include Boston Scientific.
Yes. Cortex was acquired by Boston Scientific in November 2024.